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Abstract
Drosha is a key enzyme in microRNA biogenesis, generating the precursor miRNA (pre-miRNA) by excising the
stem-loop embedded in the primary transcripts (pri-miRNA). The specificity for the pri-miRNAs and determination
of the cleavage site are provided by its binding partner DGCR8, which is necessary for efficient processing. The
crucial Drosha domains for pri-miRNA cleavage are the middle part, the two enzymatic RNase III domains (RIIID),
and the dsRNA binding domain (dsRBD) in the C-terminus. Here, we identify alternatively spliced transcripts in
human melanoma and NT2 cell lines, encoding C-terminally truncated Drosha proteins lacking part of the RIIIDb
and the entire dsRBD. Proteins generated from these alternative splice variants fail to bind to DGCR8 but still interact
with Ewing sarcoma protein (EWS). In vitro as well as in vivo, the Drosha splice variants are deficient in pri-miRNA
processing. However, the aberrant transcripts in melanoma cells do not consistently reduce mature miRNA levels
compared with melanoma cell lines lacking those splice variants, possibly owing to their limited abundance. Our find-
ings show that alternative processing-deficient Drosha splice variants exist in melanoma cells. In elevated amounts,
these alternatively spliced transcripts could provide one potential mechanism accounting for the deregulation of
miRNAs in cancer cells. On the basis of our results, the search for alternative inactive splice variants might be fruitful
in different tumor entities to unravel the molecular basis of the previously observed decreased microRNA processing
efficiency in cancer.
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Introduction
MicroRNAs (miRNAs) are single-stranded noncoding RNAs of
approximately 22 nucleotides (nt) involved in posttranscriptional
gene regulation. Their mode of action is degradation or translational
repression of target messenger RNAs (mRNAs) harboring complemen-
tary sequences [1,2]. Transcripts modulated by miRNAs are involved
in a wide range of cellular functions. Consequently, dysregulation of
miRNA biogenesis, and thus alteration in miRNA expression levels,
contributes to multiple diseases, including various forms of cancer.
In cancer cells, aberrant expression of mature miRNAs has been
frequently observed [3–9]. Deviations from the normal miRNA ex-
pression pattern could be caused, for example, by genomic deletion
or mutation, epigenetic silencing, or aberrant transcription. The
abundance of miRNA stabilizing factors could also potentially alter
miRNA activity in cancer [10,11]. In some instances, for example, for
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mir-143 and mir-145, the precursor miRNAs (pri- and pre-miRNAs)
do not differ in their quantities between normal and cancer cells,
although mature miRNA levels are decreased [12]. Thus, a deficit in
miRNA processing could be another alternative mechanism for a de-
crease in mature miRNA expression. Indeed, in some tumors, expres-
sion of key players of the miRNA biogenesis pathway is reduced or
abrogated by genomic deletion and correlates with survival and mature
miRNA levels [13–16]. Moreover, impairment of the miRNA bio-
genesis pathway by knockdown of pivotal processing factors favors
tumor formation [17].
The maturation of miRNAs is a highly complex and regulated
process, which is characterized by two cleavage reactions mediated
by RNase III enzymes [18]. Hairpin structures of long primary tran-
scripts (pri-miRNA) are first cleaved close to the base of the stem by
the Microprocessor complex, consisting of Drosha and its binding
partner DGCR8. This cropping liberates an approximately 60- to
70-nt-long hairpin structure, termed precursor miRNA (pre-miRNA)
[19–22]. Whereas the N-terminus of Drosha is required for nuclear
localization [23], the middle part of Drosha as well as the C-terminal
part, harboring the two RNase III domains, RIIIDa and RIIIDb, and
the dsRNA binding domain (dsRBD) are essential for pri-miRNA
processing [22]. The two enzymatic domains form a processing cen-
ter with two catalytic sites of RIIIDa and RIIIDb cleaving the 3′-arm
and the complementary 5′-arm of the hairpin, respectively [22]. For
the conversion of pri-miRNAs into pre-miRNAs, the interaction of
Drosha with its cofactor DGCR8 is essential [21,22]. DGCR8 con-
fers substrate specificity by recognizing the structural characteristics
of the pri-miRNA and acts as a “molecular ruler” by determining the
cleavage site within the pri-miRNA [21,24]. The basal segments, the
stem as well as the terminal loop, are structural characteristics that
play a role in cleavage site determination [24–26].
Although Drosha-mediated cleavage represents a critical process-
ing step, it is not compulsory for the generation of all pre-miRNAs.
Short introns that form hairpin structures resembling pre-miRNAs,
termed mirtrons, can be spliced and debranched into pre-miRNA
mimics, thereby omitting Drosha processing. The debranched hairpins
are then exported, and further processed by the canonical miRNA
biogenesis pathway [27–30].
After the initial cropping by the Microprocessor, the processing
intermediate is exported from the nucleus by Exportin-5 in a Ran-
dependent manner [25,31–33]. In the cytoplasm, Dicer removes the
terminal loop in a second cleavage reaction, thereby producing the
miRNA duplex of 21 to 24 nt length [34–38]. After incorporation
of one selected single strand into the effector complex RISC (RNA-
induced silencing complex) with an Argonaute protein [39,40], the
mature miRNA causes silencing of its targets by base pairing mostly
with the 3′-UTR mediating mRNA cleavage, translational repression,
or mRNA degradation [1,2].
Here, we identify novel endogenous alternative splice variants of the
important microRNA processing factor Drosha in melanoma cell lines
and NT2 embryonal carcinoma cells. These transcripts encode proteins
lacking critical functional domains, namely part of the 3′-end proximal
RNase III domain and the dsRBD. These C-terminally truncated
Drosha variants do not bind DGCR8 and hence also lack pri-miRNA
processing activity. Although processing efficiency is impaired, the
splice variants do not have a consistent major effect on the mature
miRNA repertoire of the melanoma cells most likely because of the
minor pool of alternative splice forms. However, the discovery of the
processing-deficient Drosha variants can lead the way to a thorough
search in other tumor entities where they could be more abundant
and validated as one mechanism of miRNA deregulation in cancer.
Materials and Methods
Cell Lines
Cell lines have been established from skin or lymph node metas-
tasis and were cultured as described elsewhere [41]. Patients were
experiencing histologically confirmed melanoma of the skin, mucosa,
or unknown primary and were classified as stage III or IV according
to American Joint Committee on Cancer.
Plasmids
Wild-type Drosha was cloned into pcDNA3.1D/V5-His-TOPO
as described previously [42]. The N-terminal Flag-tag was removed
and replaced by a YFP-tag using HindIII and BamHI restriction sites.
The BamHI site and the Drosha start codon were separated by the
nucleotides acc. At the end of the Drosha coding sequence, a stop
codon was introduced. RIIIDb splice variants were created by delet-
ing exon 31, exons 31 and 32, or exons 30 to 32 from pcDNA3.1D/
TOPO-YFP-Drosha-V5-His. The Drosha mutant E1045Q E1222Q
was generated by site-directed mutagenesis of pcDNA3.1D/TOPO-
YFP-Drosha-V5-His. HA-DGCR8 was created by deleting the Flag-
tag of pFLAG/HA-DGCR8, which was kindly provided by Thomas
Tuschl (Rockefeller University). The expression plasmid-encoding
pri-mir-145 was described previously [43]. All constructs were veri-
fied by sequencing. Primer sequences are listed in Table W1. Plasmid
sequences are available on request.
Reverse Transcription and Quantitative Polymerase
Chain Reaction
Total or fractionated RNA was extracted using TRIzol (Invitrogen/
Life Technologies, Carlsbad, CA) and treated with DNaseI (Roche,
Mannheim, Germany). RNA was reverse transcribed using RevertAid
H Minus Reverse Transcriptase (Fermentas, St Leon-Rot, Germany).
To test mature miRNA levels, gene-specific RT was performed using
stem-loop primers shown in Table W1 according to Chen et al. [44].
For the identification of Drosha splice variants, complementary DNA
(cDNA) of different cell lines was used as a template to amplify exons
29 to 35 of Drosha. Polymerase chain reaction (PCR) products were
visualized on a 1.2% agarose gel using ethidium bromide. Bands
that ran lower than the expected wild-type band were purified from
Ma-Mel-71, Ma-Mel-75, and NT2; cloned into pCRII-TOPO
(Invitrogen) by TOPO-TA cloning; and sequenced.
Quantitative PCR was performed on an ABI StepOne Plus using
2× Power SybrGreenMasterMix (Applied Biosystems/Life Technologies).
Primers are shown in Table W1.
Cellular Fractionation
Nuclear and cytoplasmic fractionation was basically performed
according to [45] with minor changes. In brief, Ma-Mel-71 cells were
scraped off with phosphate-buffered saline and pelleted at 300g for
5 minutes at 4°C. Pellets were resuspended in 1 ml of RSB (10 mM
Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2), incubated for 3 minutes
on ice and centrifuged at 1000g for 5 minutes at 4°C. The cell pellet
was resuspended with four times its volume of RSBG40 (10 mM Tris,
pH 7.4, 10 mM NaCl, 3 mM MgCl2, 10% glycerol, 0.5% Nonidet
P-40, 0.5 mM dithiothreitol), and 100 U/ml RNasin (Fermentas),
and 10 mM ribonucleosid vanadyl complex (NEB) were used as
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RNA inhibitor. After incubating for 3 minutes on ice and centrifuging
at 4500g for 3 minutes at 4°C, the supernatant was saved as the cyto-
plasmic fraction, and the nuclear pellet was resuspended in RSBG40
containing one-tenth volume of detergent (3.3% [wt/wt] sodium
deoxycholate and 6.6% [vol/vol] Tween-20) and incubated for 5 min-
utes on ice. Nuclei were pelleted again at 4500g for 3 minutes at
4°C, washed with RSBG40, and collected at 9300g for 5 minutes.
RNA from nuclear and cytoplasmic fraction was isolated using TRIzol
(Invitrogen) according to the manufacturer’s instructions.
Cycloheximide Treatment
Ma-Mel-71 human melanoma cells were grown to 80% confluence
and treated either with the solvent dimethyl sulfoxide or with 50 μg/ml
cycloheximide (Sigma, St Louis, MO) for 20 minutes at 37°C as de-
scribed previously [46]. The cells were then washed with phosphate-
buffered saline and lysed in TRIzol (Invitrogen) for total RNA isolation,
DNase I treatment, reverse transcription, and quantitative PCR as
described previously.
Immunoprecipitation
HEK293 cells were transfected in 10-cm dishes with a total of
24 μg of N-terminally YFP-tagged Drosha, splice variants thereof,
or empty vector with or without cotransfection of HA-DGCR8
using polyethylenimine. At 48 hours after transfection, cells were
lysed in 500 μl of cold lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1× complete
EDTA-free protease inhibitor cocktail [Roche]) for 20 minutes at
4°C under gentle shaking followed by centrifugation at 14,000g
for 15 minutes at 4°C. A ratio of 1:20 of the supernatant was saved
as input sample. The remaining lysates were incubated for 2 hours
with 30 μl of slurry of the GFP-nanotrap [47] with constant rotation.
Beads were pelleted at 400g for 2 minutes at 4°C and washed three
times with cold lysis buffer and eluted with 100 μl of sample buffer
(250 mM Tris-HCl, pH 6.8, 9.2% SDS, 40% glycerol, bromophenol
blue) boiling for 2 minutes. Samples were analyzed by 7.5% SDS-
PAGE and Western blot using the following primary antibodies:
anti-Drosha (1:500, Drosha [D28B1] XP no. 3364; Cell Signal-
ing Technology, Danvers, MA), anti-DGCR8 (1:300, 10996-1-AP;
ProteinTech Group, Inc, Chicago, IL), anti-EWS (1:1000, EWS [G-5],
sc-28327; Santa Cruz Biotechnology, Inc, Santa Cruz, CA), anti-
tubulin (1:1000, α/β-tubulin antibody no. 2148; Cell Signaling Tech-
nology), and anti-HA (1:500, Mono HA.11 MMS-101P; Covance,
Münster, Germany).
In Vivo Processing Assay
HEK293 cells were reverse transfected with the Drosha-siRNA:
5′-GCAUGCAAGCGCGGAGUAU(dTdT) or scrambled small in-
terfering RNA (siRNA) using Lipofectamine RNAiMAX in a six-well
plate. After 24 hours, the cells were transfected each with 1.5 μg of
plasmids encoding YFP-Drosha, HA-DGCR8, and pri-mir-145 to
challenge the pri-miRNA processing factors. At 48 hours after plasmid
transfection, RNA was isolated using TRIzol (Invitrogen), digested
with DNaseI (Roche), and reverse transcribed. The samples were
analyzed for pri-miRNA and endogenous Drosha levels by quantita-
tive PCR.
In Vitro Processing Assay
HEK293 cells were reverse transfected with the Drosha-siRNA:
5′-GCAUGCAAGCGCGGAGUAU(dTdT) or scrambled siRNA
using Lipofectamine RNAiMAX in a six-well plate. After 24 hours,
the cells were transfected each with 1.5 μg of plasmids encoding
YFP-Drosha and HA-DGCR8. Whole-cell extract was prepared in
a buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM KCl by
sonication, followed by centrifugation. The processing reaction (total,
35 μl) contained 40 μg of total protein, 0.5 mM ATP, 20 mM
creatine phosphate, 4 mM MgCl2, 20 U RiboLock RNase Inhibitor
(Fermentas), and 104 to 105 counts per minute of the [32P]-labeled
transcript containing pri-15b∼16-2. The assay was incubated for
30 minutes at 37°C. The T7 template for the primary transcript
was amplified by PCR (Table W1). The labeled transcript was gel
purified, precipitated, and allowed to fold for 10 minutes at 60°C
before usage (as described in Allegra and Mertens [48]).
Array
MiRNA expression profiling for melanoma cell lines was per-
formed on Illumina DASL (cDNA-mediated Annealing, Selection,
Extension, and Ligation) platform using Human miRNA Expression
Profiling V2 Panel (Illumina, San Diego, CA). Briefly, 500 ng of
total RNA was polyadenylated, reverse transcribed using a biotin-
labeled oligo-dT primer with a universal sequence at the 5′-end,
attached to a solid phase, and annealed to miRNA-specific oligo-
nucleotides that comprised three parts: another 5′ universal PCR
priming sequence, an address sequence for capturing the product
on the array, and the 3′ miRNA-specific sequence. The miRNA-
specific oligonucleotides were extended, eluted, and subjected to
PCR fluorescent universal primers. Then, single-stranded PCR prod-
ucts were prepared and hybridized to capture the probes immobilized
on beads in the arrays. Arrays were scanned by the BeadArray Reader
and intensity per bead type (miRNA) was extracted. Data were quantile
normalized using BeadStudio Data Analysis Software (Illumina).
From the normalized array data, the average signal intensities for
all 858 validated mature miRNAs (as annotated in the microRNA
registry) and for the mirtron-derived mature miRNAs miR-877 and
miR-1224-1238 were calculated. The ratio of the Drosha-dependent
mature miRNAs divided by the mirtron-derived, Drosha-independent
mature miRNAs was used as a normalized measure for genome-wide
Figure 1. Identification of alternative Drosha splice variants in melanoma cells. (A) Identification of alternative Drosha splice variants by
reverse transcription. Drosha cDNA was amplified from exon 29 to 35 by reverse transcription in several cancer cell lines (MM =Ma-Mel).
PCR products were visualized on a 1.2% agarose gel using ethidum bromide. The upper band is derived from wild-type Drosha. The lower
bands are derived from splice variants lacking exons in the amplified region. (B) Schematic representation of the Drosha gene and derived
alternative spliced mRNAs. Exon skipping changes the reading frame resulting in premature stop codons. Protein coding exons are shown
in dark gray, noncoding exons in white. Arrowheads indicate positions of primers used to amplify exon 29 to 35. Introns are not drawn to
scale. (C) Expression levels of splice variants lacking exons 31, 31 and 32, and 30 to 32 in different cancer cell lines quantified by quan-
titative RT-PCR in relation to total Drosha levels. Total Drosha levels were obtained by totaling the 2−ΔC t values normalized to RPLP0. The
sum was set as 100%. One representative data set is shown; error bars, SEM.
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Drosha-dependent processing in the cell lines. For the analysis,
six cell lines with consistently detected splice variants in reverse tran-
scription (RT)–PCR and quantitative PCR (Ma-Mel-71, Ma-Mel-
128, Ma-Mel-20, Ma-Mel-36, Ma-Mel-75, and Ma-Mel-12) were
compared to five cell lines with no significant signs of splice variant
expression (Ma-Mel-53, Ma-Mel-73, Ma-Mel-26a, Ma-Mel-122,
and Ma-Mel-8a).
Results
Drosha RIIIDb Splice Forms Exist in Several Cancer Cell Lines
To examine whether aberrant splicing of key miRNA processing fac-
tors could be a potential cause of decreased mature miRNA levels in
cancer cells, we searched for functionally inactive Drosha splice variants
in different sequence databases. We hypothesized that functional inac-
tivity of Drosha would most likely require a loss of either the RNase or
dsRNA binding activity, hence the loss of the RIIID or dsRBD
domain. Therefore, we blasted the C-terminal region of Drosha includ-
ing these three domains (NM_013235.4, nt 2985-4361) against sev-
eral nucleotide databases to determine whether expressed sequence tags
with aberrant splicing patterns had ever been identified.
This approach led to the identification of two Drosha transcripts
lacking different parts of the functional region in melanoma (GenBank
BC054003.1) and teratocarcinoma (AK308093).
To validate whether these aberrant forms exist in tumor cells, we
amplified Drosha’s C-terminus encoding the RIIIDb and the dsRBD
from cDNA of different cancer cell lines of diverse origins, several
melanoma cell lines and NT2 cells. Amplification of the wild-type
isoform with primers spanning exon 29 to 35 should yield a product
of 759 base pairs (bp) and the alternatively spliced isoforms of
BC054003.1 and AK308093 211 and 387 bp, respectively. The
wild-type product was detected in every cell line tested (Figure 1A),
but amplicons, which would reflect splicing events as in BC054003.1
and AK308093, were not produced, at least not in detectable
amounts. However, additional weaker PCR products of unexpected
size (approximately 450 bp) were observed in NT2 cells and the
melanoma cell lines Ma-Mel-71 and Ma-Mel-75 (Figure 1A). Gel
purification of these products, cloning, and subsequent sequence
analysis revealed that these transcripts lack exon 31 (identified from
NT2), exons 31 and 32 (identified from NT2 and Ma-Mel-71), or
exon 30 to 32 (identified from Ma-Mel-71, Ma-Mel-75, and Ma-
Mel-20), which code for a part of the RIIIDb (Figure 1B).
To quantitate the levels of these three alternatively spliced tran-
scripts, we performed quantitative real-time PCR using a reverse
primer in exon 35 and a forward primer specific for the individual
splice forms. Splice variants ΔE31 and ΔE31-32 contribute to less
than 3% of total Drosha levels in all cell lines tested, whereas
ΔE30-32 accounts for approximately 10% of all Drosha transcripts
in Ma-Mel-71 cells (Figures 1C and 2E ). These cells also have
already a comparably low level of wild-type Drosha (Figure W1).
Drosha RIIIDb Splice Variants Yield C-terminally Truncated
Proteins, Which Do Not Bind to DGCR8
All of the three aberrant Drosha splice variants contain premature
stop codons, encoding C-terminally truncated Drosha proteins. The
lack of E31 or E31-32 creates a stop codon of the last two nucleo-
tides of exon 30 and the first nucleotide of E32 or E33, respectively.
Thus, ΔE31 and ΔE31-32 create the same protein lacking part of the
RIIIDb and the dsRBD, ending with Glu1222 (E110b), the residue
responsible for cutting the 5′ arm of the pri-miRNA hairpin [22].
Deletion of E30-32 creates a frameshift leading to a sequence of
44 amino acids different from the wild-type before creation of a
premature stop codon. The encoded protein lacks more than half
of the RIIIDb and the dsRBD (Figure 2, A and B).
Processing of pri-miRNA into pre-miRNA not only requires the
RNase III Drosha but also necessitates the cofactor DGCR8 [21,22],
which interacts with the middle region as well as the RIIIDs of
Drosha [22]. Because the alternative splice variants lack part of
RIIIDb, we tested whether they are still able to bind DGCR8.
To this end, we transfected HEK293 cells with plasmids encoding
N-terminally YFP-tagged Drosha proteins with wild-type or alterna-
tively spliced sequences. The expression levels of the spliced forms are
similar to that of wild-type protein (Figure 2C , left panel ). On YFP
pull-down, endogenous (Figure 2C ) or ectopic (Figure 2D) DGCR8
coprecipitated with wild-type Drosha but not with the three alterna-
tively spliced isoforms. On the contrary, another interaction partner
of Drosha, the Ewing sarcoma protein [21], was still associated with
the RIIIDb splice variants to the same extent as with the wild-type
(Figure 2C ). Hence, lack of the dsRBD and part of the RIIIDb re-
sults in loss of DGCR8 binding but has no impact on interaction
with EWS.
Drosha RIIIDb Splice Variants Exist in the Cytoplasm
Alternative splicing of exon E31, E31-32 or E30-32 generates pre-
mature termination codons, which could potentially make the variant
transcripts prone to nonsense-mediated decay (NMD). To find out,
whether Drosha RIIIDb alternatively spliced transcripts are degraded
by NMD or whether they are stable, we examined mRNA levels of
wild-type Drosha and the splice variants in nuclear and cytoplasmic
fractions of Ma-Mel-71 cells. To verify the purity of the fractions, we
monitored pre-45S rRNA and the tRNALys, which showed a clear
nuclear and cytoplasmic enrichment, respectively (data not shown).
Figure 2. Drosha splice variants do not bind DGCR8. (A) Schematic overview of Drosha splice variants and their protein products. The
two conserved RNase III domains and the double-stranded RNA binding domain are indicated (RIIIDa, RIIIDb, dsRBD) according to the
SMART program (http://smart.embl-heidelberg.de/). (B) Sequence alignment of Drosha wild-type and alternative splice variants. Amino
acids coding for the RIIIDb are highlighted in dark gray, amino acids coding for the dsRBD in light gray. (C, D) Novel alternative splice
variants do not bind DGCR8. YFP-tagged WT and alternatively spliced Drosha were overexpressed in HEK293 cells without (C) or with (D)
coexpression of HA-DGCR8. Cells were lysed 48 hours after transfection, and Drosha was pulled down using the GFP-nanotrap. The
eluate was analyzed by SDS-PAGE and Western blot analysis using anti-Drosha, anti-DGCR8, anti-HA, anti-EWS, and anti-tubulin anti-
bodies. Tubulin served as loading control. EV indicates empty vector; EWS, Ewing sarcoma protein; WT, wild-type. (E) Ma-Mel-71
shows the same percentage of Drosha ΔE30-32 splice variants expression in total, cytoplasmic, and nuclear fractions as determined
by quantitative RT-PCR. Total Drosha levels were obtained by totaling the 2−ΔC t values normalized to RPLP0. The sum was set as 100%.
n = 3. Error bars, SEM.
242 Processing-Deficient Drosha Splice Variants Grund et al. Neoplasia Vol. 14, No. 3, 2012
Neoplasia Vol. 14, No. 3, 2012 Processing-Deficient Drosha Splice Variants Grund et al. 243
The distribution of wild-type and alternatively spliced Drosha tran-
scripts was consistent in total, nuclear, and cytoplasmic fractions
(Figure 2E). Hence, the cytoplasmic stability of wild-type and alterna-
tively spliced Drosha transcripts seems to be comparable, suggesting
that the novel splice forms are not degraded by NMD. To formally
prove that Drosha ΔE30-32 is not subject to NMD, we treated
Ma-Mel-71 cells with cycloheximide, which inhibits NMD by block-
ing translation [46]. Quantification of wild-type and alternatively
spliced Drosha revealed that cycloheximide treatment did not increase
the expression of the alternatively spliced isoforms indicating that the
isoform is not subject to NMD (Figure W2).
Drosha RIIIDb Splice Variants Are Deficient in pri-miRNA
Processing Activity
Drosha processing requires DGCR8 binding and two intact
RIIIDs [21,22]. To determine whether Drosha proteins generated from
RIIIDb alternative transcripts are catalytically inactive, we tested their
ability to process pri-miRNA in vitro and in vivo.
For the in vitro processing assay, lysates of cells overexpressing
DGCR8 and wild-type or mutant Drosha constructs were incubated
with radioactively labeled pri-miR-16-2. As negative controls, we used
cells transfected with empty vector or a transdominant-negative,
processing-deficient Drosha mutant (TN-Drosha) containing point
mutations in both RNase III domains (E1045Q E1222Q) [49].
Only lysate containing wild-type Drosha was capable of generating
pre-mir-16-2, whereas the three Drosha splice variants as well as
empty vector and TN-Drosha were unable to execute pri-miRNA
processing (Figure 3A).
To confirm this result in vivo, we determined pri-miRNA levels by
quantitative PCR on endogenous Drosha knockdown and subse-
quent overexpression of DGCR8 and wild-type or alternatively
spliced Drosha. The siRNA was designed to target the 3′-UTR of
the endogenous Drosha mRNA, so that only the endogenous not
the ectopically expressed Drosha was silenced. Knockdown efficiency
was monitored both at the mRNA and protein levels compared with
control siRNA-treated cells by quantitative PCR and Western blot.
Endogenous Drosha mRNA levels dropped to less than 60%
(Figure W3A), and a much more potent down-regulation was ob-
served at protein level (Figure W3B). Ectopic Drosha constructs were
not affected by the siRNA (Figure W3B). On Drosha knockdown,
we observed that pri-miRNAs accumulated (data not shown).
Expression of wild-type Drosha significantly diminished pri-miR-
NA levels compared with cells transfected with empty vector or YFP.
In accordance with the in vitro assay results, the Drosha splice variants
did not exhibit processing activity because no change in pri-miRNA
levels was observed (Figure 3B). Also, the DGCR8 mRNA, which is
also a substrate for Drosha cleavage [50–52], was only processed by
wild-type Drosha but not by the splice variants (Figure 3C ).
Upon overexpression of TN-Drosha, pri-miRNA levels accumu-
lated (Figure W3C) as described previously [50]. To take into consid-
eration that Drosha splice variants could be marginally less expressed
than wild-type Drosha, we transfected cells with only half of the
amount of the wild-type Drosha construct (WT 12). This resulted in
a comparable expression of Drosha wild-type and splice variants at the
protein level (Figure W3B). Nevertheless, pri-miRNA processing effi-
ciency closely resembles that of cells transfected with the full amount of
wild-type Drosha (Figure W3C). Thus, the difference in pri-miRNA
expression (Figure 3, B and C) was due to a difference in processing
activity in vivo, but not due to a potential difference in expression of
the splice variants compared with wild-type Drosha.
Melanoma Cell Lines with Alternatively Spliced Drosha
Variants Do Not Show Generally Decreased Mature
MiRNA Levels
To test whether the Drosha RIIIDb splice variants affected mature
miRNA levels, we determined the expression of 858 mature miRNAs
using a microarray platform in eleven melanoma cell lines which con-
sistently showed Drosha splice variants (n = 6) or no sign of splice
variants (n = 5) in RT-PCR and quantitative PCR. For normalization
purposes, we used average levels of mature mirtrons, which are de-
rived from Drosha-independent substrates as they are generated by
splicing [27,28]. Indeed, the average mature miRNA levels of cell
lines expressing Drosha splice variants were lower than in the control
cell lines, but this strong trend was not significant (P = .096, t test).
On the contrary, the cell line with the highest level of splice variants,
Ma-Mel-71, exhibited the highest mature miRNA levels within the
group with splice variants (Figure 4A). Thus, these results were am-
bivalent with respect to the impact of Drosha splice variants on ma-
ture miRNA expression: Whereas a trend indicates decreased mature
miRNA abundance coinciding with low-abundance Drosha splice
variants, the cell line with the by-far highest level of processing defi-
cient splicing variants did not follow this pattern.
Further, we investigated the levels of individual mature miRNAs,
miR-17 and miR-25, relative to their respective pri-miRNA expression
in cell lines expressing RIIIDb splice variants (Ma-Mel-71,Ma-Mel-75,
andMa-Mel-36) and cell lines with no detectable Drosha splice variants
(Ma-Mel-8a and Ma-Mel-73a) by quantitative PCR. For both miRNAs,
no significant correlation between the amount of splice variants and
mature miRNA levels could be observed (Figure 4B).
Overall, these results suggest that, although alternatively spliced
Drosha variants are pri-miRNA processing deficient, the amount in
the tested cell lines might not be sufficient to consistently affect mature
miRNA production.
Discussion
At least 30% of all human genes are predicted to be controlled by
miRNAs [53]. Because many targets are involved in key cellular pro-
cesses, deregulation of miRNA biogenesis and finally aberrant miRNA
levels are associated with a variety of diseases, particularly cancer.
Although several miRNAs are overexpressed in cancer cells, most
miRNAs shows reduced expression in human tumors [3,4,8]; reviewed
in references [54–56]. This phenotype could be attributed to altered
levels of functional processing factors, which we hypothesized could
be caused by aberrant alternative splicing. Our analyses focused on
the major nuclear pri-miRNA processing enzyme Drosha, which is es-
sential for the production of most mature miRNAs except the mirtrons.
Moreover, other key factors of the miRNA biogenesis pathway might
be subject to alternative splicing, as was previously shown for Dicer in
neuroblastoma cell lines [57].
In this study, we identify novel alternative splice variants of the
human Drosha gene in melanoma cell lines, which differ in their
coding sequence and encode functionally inactive Drosha proteins.
Skipping of exon E31, E31-32, or E30-32 changes the reading frame,
leading to a premature stop codon.
Transcripts containing a stop codon that prematurely terminates
translation can be eliminated by a quality mechanism, termed nonsense-
mediated decay, to avoid the generation of truncated proteins that could
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Figure 3. Drosha splice variants are defective in pri-miRNA processing activity. HEK293 cells depleted of endogenous Drosha using an
siRNA against the 3′UTR of Drosha were transfected with HA-DGCR8 and siRNA-resistant Drosha constructs as indicated. EV indicates
empty vector; WT, wild-type. (A) The cell lysates were incubated with labeled pri-mir-16-2 to assay pri-miRNA processing activity in vitro.
(B, C) Quantification of several pri-miRNA levels (B) and endogenous DGCR8 mRNA levels (C) by quantitative RT-PCR normalized to
cyclophilin mRNA levels. n = 3. Error bars, SEM. Asterisks denote statistically significant differences: *P < .05, **P < .01, ***P <
.001 (unpaired t test).
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have dominant-negative or otherwise detrimental effects. This process
itself is interestingly also regulated by microRNAs [58,59]. Stop codons
are sensed as premature and elicit NMD, for example, when they are
followed by an exon-exon junction located more than 50 to 55 nt
downstream [60]. Drosha ΔE31 and Drosha ΔE31-32 splice variants
fulfill this criterion, as the premature stop codon is followed by three or
two exon-exon junctions, respectively, more than 55 nt downstream,
and hence, they might be targeted for degradation by the NMD ma-
chinery. In contrast, removal of E30-32 creates a premature stop codon
only at the last but one exon, exon 34, 5 nt upstream of the last exon-
exon boundary. The most abundant transcript variant, Drosha ΔE30-
32, should thus escapeNMD and be translated into a truncated Drosha
protein. The fact that the splice variants exist in cytoplasmic fractions of
Ma-Mel-71 cells to the same extent as in total lysates argues in favor of
transcripts that are stable and translated rather than rapidly degraded by
the cytoplasmic NMD machinery. In addition, expression of the trun-
cated variants from plasmids leads to approximately the same level of
protein as expression of wild-type Drosha. Hence, the truncation does
not compromise the structure in a way that leads to degradation of the
protein. Lastly, inhibiting NMD using cycloheximide in Ma-Mel-71
cells did not alter the abundance of Drosha ΔE30-32 proving that it
is not subject to NMD. Summing up, at least the most abundant splice
variant Drosha ΔE30-32 is most likely translated into a truncated
Drosha protein.
The encoded truncated proteins are lacking the dsRBD and part of
the RIIIDb. Previous studies have shown that the dsRBD as well as
two intact RIIIDs are required for cropping of the pri-miRNA [22].
The two enzymatic RIIIDs form a single processing center with two
catalytic sites by intramolecular dimerization [22]. In addition, the
interaction of DGCR8 with Drosha is needed for efficient cleavage
[21,22] because Drosha alone does not exhibit pri-miRNA-binding
activity [61]. We demonstrated that Drosha RIIID splice variants do
not bind DGCR8, showing that two complete RIIIDs are required
for DGCR8 binding. Consistently, Drosha splice forms are deficient
in pri-miRNA processing in vitro as well as in vivo.
Although the ectopic isoforms did not exhibit DGCR8 binding or
pri-miRNA processing activity, there was no consistent impact of the
endogenous alternatively spliced Drosha transcripts in melanoma cell
lines on mature miRNA production. Expression profiling indicates
decreased miRNA expression associated with the Drosha splice
Figure 4. Cell lines with low levels of Drosha splice variants do not show consistently reduced miRNA levels. (A) Average mature miRNA
expression levels from microarrays normalized to average mature mirtron levels. Cell lines with alternative splicing events at the C-terminus
(SV) versus cell lines without detectable splicing events within exon 29 to 35 (no SV). The horizontal bars represent average values in the
respective groups. (B) Expression levels of mature miRNAs, miR-25 and mir-17, normalized to the respective pri-miRNAs in different
melanoma cell lines. The average miRNA level of Ma-Mel-8a and Ma-Mel-73a was set as 1. Bars indicate average expression; error bars,
SEM (n = 3).
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variants, but paradoxically, Ma-Mel-71 cells, which exhibit the high-
est amounts of RIIID spliced transcripts among the cell lines tested,
show high mature-to-pri-miRNA ratios, that is, good pri-miRNA pro-
cessing. It could be possible that another factor involved in miRNA
biogenesis might be altered in Ma-Mel-71 cells, which could over-
shadow the effect of the Drosha splice variants.
Given the importance of Drosha as a key player in miRNA bio-
genesis, it is most likely that sufficient amounts of alternatively
spliced Drosha transcripts show a more pronounced effect on miRNA
maturation. This could be envisioned in two ways: either the trun-
cated transcripts are translated into nonfunctional proteins that execute
dominant-negative functions or, in case the transcripts are degraded,
wild-type RNA levels would be reduced resulting in limiting amounts
of wild-type Drosha transcripts and thus less functional Drosha protein.
As shown before, the artificial decrease in Drosha expression can lead to
decreased miRNA activity and enhanced tumorigenesis [17]. In addi-
tion, a decrease of Drosha mRNA and protein in ovarian cancer [62] as
well as neuroblastoma has been associated with a global miRNA down-
regulation [63] corroborating the significance of Drosha regulation in
cancer. Thus, our data suggest that the search for more strongly ex-
pressed Drosha splice variants might be fruitful in other tumor entities
and might provide one way to solve the many open questions about
miRNA deregulation and processing defects in human cancer.
In summary, we have discovered rare splice variants of the impor-
tant miRNA biogenesis factor Drosha for the first time. In melanoma,
these splice variants lack parts of one RNase domain as well as the
dsRBD. They thus do not bind DGCR8 and are completely deficient
in miRNA processing in vivo and in vitro. However, the variants lack a
consistent effect on endogenous miRNA expression in melanoma cell
lines. Thus, this study shows that processing-deficient splice variants
of important processing factors exist and could impact the miRNA
expression patterns found in human tumors. For the future, it will
be of great interest to search for tumor-enriched processing-deficient
splice variants in the miRNA biogenesis pathway to understand the
mechanisms underlying the frequently observed deregulation of ma-
ture miRNAs in cancer beyond the transcriptional level.
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Table W1. Primer Sequences.
Cloning
Target Forward Reverse
YFP 5′-gtgtgtaagcttaccatggtgagcaagggcgaggagc 5′-acacacggatccgagcttcttgtacagctcgtccatgc
Drosha ΔE31 5′-ccttggcggaccttttggaatgagttcattttgaatcag 5′-ctgattcaaaatgaactcattccaaaaggtccgccaagg
Drosha ΔE31-32 5′-ccttggcggaccttttggaatgactctgcagacagtgg 5′-ccactgtctgcagagtcattccaaaaggtccgccaagg
Drosha ΔE30-32 5′-catgaaggacacttaactgactctgcagacagtgg 5′-ccactgtctgcagagtcagttaagtgtccttcatg
Flag deletion to obtain HA-DGCR8 5′-ctgatcgccgccgccatgtacccttatgacgtgc 5′-gcacgtcataagggtacatggcggcggcgatcag
Drosha E1045Q 5′-ggccaattgttttcaagcgttaatagg 5′-cctattaacgcttgaaaacaattggcc
Drosha E1222Q 5′-ggcggaccttttgcaatcatttattgcagcg 5′-cgctgcaataaatgattgcaaaaggtccgcc
Specific RT for Mature miRNAs
Target Stem-loop Primer
miR-17 5′-gtcgtatccagtgcagggtccgaggtattcgcactggatacgacctacct
miR-25 5′-gtcgtatccagtgcagggtccgaggtattcgcactggatacgactcagac
PCR
Target Forward Reverse
Drosha E29-35 5′-ccacaatcagagaatggaattcc 5′-gacaacagtcacagttactgagc
Quantitative PCR
Target Forward Reverse
WT Drosha 5′-gcttctttccacgattgaaagag 5′-ccattgctgctcccatttcc
Drosha ΔE31 5′-ggcggaccttttggaatgag 5′-ccattgctgctcccatttcc
Drosha ΔE31-32 5′-gcggaccttttggaatgactc 5′-ccattgctgctcccatttcc
Drosha ΔE30-32 5′-atcatgaaggacacttaactgac 5′-ccattgctgctcccatttcc
Endogenous Drosha 5′-gtgacatatccaggcggaac 5′-gaagcagcctcagattttgg
Endogenous DGCR8 (5′UTR) 5′-actcgcttagtcgccagtca 5′-ggccacattgctcttttcat
pri-let-7a-3 5′-accaagaccgactgcccttt 5′-ctctgtccaccgcagatatt
pri-miR-17 5′-acatcaccttgtaaaactgaagattg 5′-aaaaagcactcaacatcagcag
pri-miR-25 5′-ggtcgcctactcacaaaacag 5′-ctcacaggacagctgaactcc
pri-miR-16-2 5′-tgttttcatcatcagatgttcgt 5′-agttgctgtatccctgtcacac
miR-17 5′-gtcgtatccagtgcagggtccgaggtattcgcactggatacgacctacct 5′-gtgcagggtccgaggt
miR-25 5′-gtcgtatccagtgcagggtccgaggtattcgcactggatacgactcagac 5′-gtgcagggtccgaggt
Cyclophilin A 5′-gtcaaccccaccgtgttctt 5′-ctgctgtctttgggaccttgt
RPLP0 5′-ggcgacctggaagtccaact 5′-ccatcagcaccacagccttc
Pre-45S rRNA 5′-cggtcgtgtgtgggttgact 5′-ctccttccttccgaggcaga
tRNALys 5′-cccgaacagggacttgaac 5′-gcccggatagctcagtcg
Primary MiRNA Processing
Target t7_Forward Reverse
pri-miR-15b∼16-2 5′-taatacgactcactatagggctaggttggatgaatccta 5′-aatacaaacaattgataaaatag
Figure W1. Drosha wild-type expression in different cell lines. Relative expression levels of wild-type Drosha mRNA were quantified by
quantitative PCR using primers specific for the wild-type sequence. Values are normalized to RPLP0 levels. One representative data set
is shown; error bars, SEM.
Figure W2. Drosha ΔE30-32 splice variant is not subject to NMD.
Ma-Mel-71melanoma cells were treated with cycloheximide to block
the initial roundof translation required forNMD.Theexpression of the
DroshaΔE30-32 splice variant as quantified by quantitative RT-PCR in
comparison to wild-type Drosha remained unchanged when NMD
was blocked, indicating that it is not subject to NMD. Depicted is
the average of three experiments, with error bars representing SEM.
Figure W3. Drosha splice variants exhibit no pri-miRNA processing activity. HEK293 cells depleted of endogenous Drosha using an
siRNA against the 3′UTR of Drosha were transfected with HA-DGCR8 and siRNA-resistant Drosha constructs as indicated. WT 1/2
indicates that half the amount of Drosha WT plasmid was used for transfection. EV indicates empty vector; WT, wild-type. (A) Endog-
enous Drosha levels were determined by quantitative RT-PCR to verify knockdown efficiency. (B) Protein expression levels of endoge-
nous and ectopic Drosha were analyzed by Western blot. (C) Quantification of pri-miRNA levels by quantitative RT-PCR normalized to
cyclophilin mRNA levels. n = 3. Error bars, SEM. Asterisks denote statistically significant differences: *P < .05, **P < .01, ***P < .001
(unpaired t test).
